A Case of Butane Hash Oil (Marijuana Wax)–Induced Psychosis
Corey J. Keller, Evan C. Chen, Kimberly L. Brodsky, Jong H. Yoon
Substance Abuse January 28, 2016 DOI: 10.1080/08897077.2016.1141153 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A 34-year-old male veteran |
| Interventions | Marijuana wax Risperidone |
| Dose | risperidone 4 mg twice a day (BID) |
| Duration | Hospitalization with improvement on day 8; follow-up after discharge not specified |
| Topics | Cannabis |
| Citations | 27 |
| Key findings | A 34-year-old veteran developed profound psychosis after heavy daily use of high-potency marijuana "wax"; symptoms persisted on risperidone 4 mg twice daily but resolved by day 8 of hospitalization, and no psychotic symptoms returned after he stopped all marijuana use. The authors argue that high-potency cannabis products need research into possible dose-dependent psychiatric effects. |
Abstract
Background: Marijuana is one of the most widely used controlled substances in the United States. Despite extensive research on smoked marijuana, little is known regarding the potential psychotropic effects of marijuana "wax," a high-potency form of marijuana that is gaining in popularity. CASE: The authors present a case of "Mr. B," a 34-year-old veteran who presented with profound psychosis in the setting of recent initiation of heavy, daily marijuana wax use. He exhibited incoherent speech and odd behaviors and appeared to be in a dream-like state with perseverating thoughts about his combat experience. His condition persisted despite treatment with risperidone 4 mg twice a day (BID), but improved dramatically on day 8 of hospitalization with the return of baseline mental function. Following discharge, Mr. B discontinued all marijuana use and did not exhibit the return of any psychotic symptoms.
Discussion: This study highlights the need for future research regarding the potential medical and psychiatric effects of new, high-potency forms of marijuana. Could cannabis have a dose-dependent impact on psychosis? What other potential psychiatric effects could emerge heretofore unseen in lower potency formulations? Given the recent legalization of marijuana, these questions merit timely exploration.
Comparable studies
Other case reports and case series on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychotic Reactions Following Cannabis Use in East Indians Patients at an Indian drug addiction clinic who developed acute cannabis-related psychosis | 1974 | Descriptive report (case series of clinical observations) | n = 200 |
| Psychiatric effects of cannabis use Swedish cases of cannabis psychosis | 1985 | Case series | n = 70 |
| Forty-Six Cases of Psychosis in Cannabis Abusers Gunila Bernhardson Habitual cannabis users treated for psychosis at Swedish psychiatric clinics and mental... | 1972 | Case series (retrospective survey of psychiatric records) | n = 46 |
| Hallucinogen persisting perception disorder after psilocybin consumption: a case study 18-year-old man with HPPD after mixed psilocybin and cannabis intoxication | 2005 | Case study | n = 1 |
| Cannabis‐induced Koro in Americans American men aged 22-26 with years of cannabis experience who reported negative... | 2001 | Case series | n = 3 |
Citations in the library
Cited by 2
Cites 4
- High-potency cannabis and the risk of psychosis The British Journal of Psychiatry November 30, 2009
- Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light Frontiers in Behavioral Neuroscience 2011
- The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine October 2009
- The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology August 2004